Tyra Biosciences says first patient dosed in Phase 2 study of TYRA-300

Tyra Biosciences (TYRA) announced that the first patient has been dosed in the Phase 2 SURF302 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cancer. TYRA-300 will also be evaluated in pediatric achondroplasia in the BEACH301 Phase 2 study, which is open for enrollment and for which the company now expects first child dosing in the second half of the year.